AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 16, 2024
Part algae, part red blood cell, these microrobots can travel to hard-to-reach tumors deep in the lungs. (Zhang et al., Sci. Adv., 2024/CC BY-NC) Tumors that travel to the lungs, or lung metastases, pose a formidable challenge in the realm of cancer treatment. Conventional chemotherapy often falls short because it’s inefficient.
Pharmaceutical Technology
JUNE 16, 2024
Based on the latest STARGLO trial results, there is potential to extend Columvi into earlier lines of therapy for diffuse large B-cell lymphoma (DLBCL).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 16, 2024
J&J’s ‘Swiss army knife’ for autoimmune diseases, FcRn inhibitor nipocalimab, has shown efficacy in Sjogren’s disease
Fierce Pharma
JUNE 16, 2024
Roche’s up-and-coming Columvi has demonstrated it could save lives when used as a second-line therapy in diffuse large B-cell lymphoma. | Roche’s up-and-coming Columvi has shown it could save lives when used as a second-line therapy in diffuse large B-cell lymphoma. But the company still finds itself fielding questions about the bispecific drug’s market potential thanks to an imbalance noticed in the phase 3 data.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
JUNE 16, 2024
AstraZeneca’s Calquence improved progression-free survival in previously untreated mantle cell lymphoma in the ECHO trial
BioSpace
JUNE 16, 2024
The use of artificial intelligence in the development of cancer vaccines allows for individualized therapy, but the prospect of an ever-changing product poses new challenges for drug developers and regulators.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
JUNE 16, 2024
The plethora of genes involved in obesity presents an intriguing opportunity for both gene silencing and ex vivo gene therapy approaches.
Drug Patent Watch
JUNE 16, 2024
This chart shows the patent expirations for tablet dosed drugs over the next decade. The term of drug patents varies.
BioSpace
JUNE 16, 2024
Shifts in the FDA’s approach present an unprecedented opportunity to solve problems with patient access and trial design.
Drug Patent Watch
JUNE 16, 2024
Annual Drug Patent Expirations for RECARBRIO Recarbrio is a drug marketed by Msd Merck Co and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.
BioSpace
JUNE 16, 2024
Takeda’s soticlestat, licensed from Ovid Therapeutics, did not significantly reduce seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome, respectively, according to two late-stage readouts on Monday.
Drug Patent Watch
JUNE 16, 2024
Annual Drug Patent Expirations for GAVRETO Gavreto is a drug marketed by Blueprint Medicines and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
BioSpace
JUNE 16, 2024
Johnson & Johnson’s FcRn inhibitor nipocalimab in a mid-stage study significantly improved disease activity across various organ systems in patients with the chronic autoimmune Sjögren’s disease.
Drug Patent Watch
JUNE 16, 2024
Annual Drug Patent Expirations for PLUVICTO Pluvicto is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
JUNE 16, 2024
The hold on BioNTech and MediLink’s antibody-drug conjugate candidate BNT326/YL202 has halted enrollment in a Phase I U.S. trial in patients with non-small cell lung cancer or breast cancer, following multiple deaths.
Drug Patent Watch
JUNE 16, 2024
Annual Drug Patent Expirations for INGREZZA+SPRINKLE Ingrezza Sprinkle is a drug marketed by Neurocrine and is included in one NDA. It is available from one supplier.
BioSpace
JUNE 16, 2024
The FDA has a packed calendar this week, with six decisions on the docket, including ones for Merck’s Keytruda, BMS's Krazati and Sarepta’s Elevidys.
JAMA Internal Medicine
JUNE 16, 2024
This essay describes the importance of physicians using positive reframing with patients.
BioSpace
JUNE 16, 2024
Novo Nordisk CEO Lars Jørgensen has agreed to appear before the Senate health committee in a hearing on the prices of its blockbuster drugs Ozempic and Wegovy.
BioSpace
JUNE 16, 2024
AstraZeneca on Monday secured FDA approval for its blockbuster Imfinzi, in combination with chemotherapy, to treat adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
BioSpace
JUNE 16, 2024
A final analysis of Gilead Sciences’ now-discontinued Phase III ENHANCE study showed a worrying trend of increased death risk in myelodysplastic syndromes patients treated with magrolimab.
Expert insights. Personalized for you.
212 
Let's personalize your content